title: Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension.
abstract: Casein hydrolysate, prepared with Aspergillus oryzae protease, contains angiotensin I-converting enzyme inhibitory peptides, such as Val-Pro-Pro and Ile-Pro-Pro. We conducted a randomized, double-blind, placebo-controlled study to evaluate the effect of casein hydrolysate on the blood pressure of 144 subjects with high-normal blood pressure (n = 104) and mild hypertension (n = 40). Subjects were randomly assigned to two groups for a 12-week intake period. In the test group, both systolic (SBP) and diastolic (DBP) blood pressure decreased significantly compared with the placebo group: SBP/DBP significantly decreased from 138.2 +/- 6.5/84.4 +/- 5.3 mm Hg at week 0 to 132.3 +/- 7.3 (P < .001)/81.2 +/- 4.8 mm Hg (P < .001) at week 12. In the stratified analysis, the test product showed an antihypertensive effect in both the subject group with high-normal blood pressure and that with mild hypertension. No side effect was observed in any subjects in this study. These results demonstrate that the casein hydrolysate, prepared with A. oryzae protease, produced a significant reduction in blood pressure in a population of subjects with high-normal blood pressure or mild hypertension without an adverse event.
authors.affiliation: R&D Center, Calpis Co., Ltd., Kanagawa, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Sano
authors.forename: Kohji
authors.initials: K
authors.lastname: Ohki
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Higuchi
authors.forename: Kotaro
authors.initials: K
authors.lastname: Aihara
authors.forename: Seiichi
authors.initials: S
authors.lastname: Mizuno
authors.forename: Osami
authors.initials: O
authors.lastname: Kajimoto
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nakagawa
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Kajimoto
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D001236:Aspergillus oryzae / Q000201:enzymology*; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D002364:Caseins / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D004032:Diet; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000378:metabolism*; D010919:Placebos; D011188:Potassium / Q000652:urine; D012964:Sodium / Q000652:urine
chemical_list: D002364:Caseins; D010919:Placebos; C475729:casein hydrolysate; D012964:Sodium; D010447:Peptide Hydrolases; D011188:Potassium